Guohai Securities released a research report on April 26 stating that it gave Ruipu Biotech (300119.SZ) a purchase rating. The main reasons for the rating include: 1) business performance bucking the trend; 2) the successful launch of the cat triple vaccine, which is expected to achieve import substitution; 3) with the acquisition of Biwei Antai, the livestock vaccine business is expected to grow rapidly. (Mainichi Keizai Shimbun)
国海证券4月26日发布研报称，给予瑞普生物（300119.SZ）买入评级。评级理由主要包括：1）经营业绩逆势增长；2）猫三联疫苗成功上市，有望实现进口替代；3）收购必威安泰，畜用疫苗业务有望快速增长。（每日经济新闻）
Guohai Securities released a research report on April 26 stating that it gave Ruipu Biotech (300119.SZ) a purchase rating. The main reasons for the rating include: 1) business performance bucking the trend; 2) the successful launch of the cat triple vacci
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.